BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -88.04% | -17.28% | 3.92% | 52.75% | 73.82% |
| Total Depreciation and Amortization | -8.14% | -2.91% | -2.26% | -2.24% | -2.85% |
| Total Amortization of Deferred Charges | 133.07% | 253.75% | 154.53% | 30.13% | -28.53% |
| Total Other Non-Cash Items | 139.71% | 144.72% | 230.14% | -656.63% | -229.22% |
| Change in Net Operating Assets | 238.90% | 394.88% | 126.49% | 1,244.67% | -135.97% |
| Cash from Operations | 13.54% | 20.01% | 30.76% | 47.06% | 44.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -224.32% | -- | -- | -- | -- |
| Issuance of Common Stock | 95.30% | 46.50% | 69.36% | -37.52% | -8.23% |
| Repurchase of Common Stock | 70.91% | 68.52% | -687.50% | -487.50% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 17.07% | -239.03% | -205.48% | -87.43% | -214.36% |
| Cash from Financing | 87.42% | 54.17% | 59.81% | -46.94% | -19.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.93% | 96.90% | 93.81% | 47.11% | 52.80% |